#ASH18: BeiGene works to bust through the checkpoint crowd with a pivotal readout that proves its PD-1 is better than the rest
With 2 pioneering PD-1s lording it over the 6 approved checkpoints in its class, what difference can 1 more make?
The executive team at BeiGene is glad you asked.
On Monday, the Chinese biotech posted some remarkable results for their pivotal study aimed at gaining a quick OK in China for their PD-1 tislelizumab in treatment-resistant classical Hodgkin’s lymphoma. And they’re taking their best shot at making a case in San Diego that this one could be significantly better than its many rivals.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 90,500+ biopharma pros reading Endpoints daily — and it's free.